Johnston, Brian D.
Thuras, Paul
Porter, Stephen B.
Anacker, Melissa
VonBank, Brittany
Vagnone, Paula Snippes
Witwer, Medora
Castanheira, Mariana
Johnson, James R. http://orcid.org/0000-0002-9588-5045
Funding for this research was provided by:
Cipla
Allergan
Merck
Melinta
Shionogi
Tetraphase
Biomedical Laboratory Research and Development, VA Office of Research and Development
Article History
Received: 13 May 2021
Accepted: 8 July 2021
First Online: 19 July 2021
Declarations
:
: The study was approved by the MVAMC Institutional Review Board.
: Not applicable.
: Not applicable.
: James R. Johnson has had grants and/or consultancies with Allergan/Actavis, Cipla/Achaogen, Janssen/Crucell, Melinta/The Medicines Company, Merck, Shionogi, Syntiron, and Tetraphase.Mariana Castanheira is an employee of JMI Laboratories. JMI Laboratories contracted to perform services in 2019 for Achaogen, Inc., Albany College of Pharmacy and Health Sciences, Allecra Therapeutics, Allergan, AmpliPhi Biosciences Corp., Amicrobe Advanced Biomaterials, Amplyx, Antabio, American Proficiency Institute, Arietis Corp., Arixa Pharmaceuticals, Inc., Astellas Pharma Inc., Athelas, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Dickinson and Company, bioMerieux SA, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., CorMedix Inc., DePuy Synthes, Destiny Pharma, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, U.S. Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Harvard University, Helperby, HiMedia Laboratories, F. Hoffmann-La Roche Ltd., ICON plc, Idorsia Pharmaceuticals Ltd., Iterum Therapeutics plc, Laboratory Specialists, Inc., Melinta Therapeutics, Inc., Merck & Co., Inc., Microchem Laboratory, Micromyx, MicuRx Pharmaceuticals, Inc., Mutabilis Co., Nabriva Therapeutics plc, NAEJA-RGM, Novartis AG, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pfizer, Inc., Polyphor Ltd., Pharmaceutical Product Development, LLC, Prokaryotics Inc., Qpex Biopharma, Inc., Roivant Sciences, Ltd., Safeguard Biosystems, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Spero Therapeutics, Summit Pharmaceuticals International Corp., Synlogic, T2 Biosystems, Inc., Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetraphase Pharmaceuticals, Theravance Biopharma, University of Colorado, University of Southern California-San Diego, University of North Texas Health Science Center, VenatoRx Pharmaceuticals, Inc., Viosera Therapeutics, Vyome Therapeutics Inc., Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, and Zavante Therapeutics, Inc. She has no speakers’ bureaus or stock options to declare.The other authors report no financial conflicts of interest.
: The opinions expressed here are strictly those of the authors and do not necessarily represent those of the Department of Veteran Affairs or the authors' institutions.